Kidney cancer encompasses a wide spectrum and can present with extensive metastases or just a handful. However, today all patients are treated the same. They all receive medication. Investigators report the results of a clinical trial exploring the role of stereotactic ablative radiation therapy (SAbR) for patients with a handful of metastases, or so-called oligometastatic disease. The study represents the first clinical trial for patients with untreated oligometastatic kidney cancer. Each year brings more than 430,000 new cases of kidney cancer worldwide and nearly 180,000 deaths, according to the World Health Organization. About 40% of patients develop metastatic disease. Metastatic...